An Open-label, Uncontrolled Phase II-study to Investigate Pharmacokinetics, Safety and Biomarkers of Effectiveness of NeuroSTAT (Ciclosporin) in Patients With Severe Traumatic Brain Injury (TBI)
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2018
Price : $35 *
At a glance
- Drugs Ciclosporin (Primary)
- Indications Traumatic brain injuries
- Focus Adverse reactions; First in man; Pharmacokinetics
- Acronyms CHIC
- Sponsors NeuroVive Pharmaceutical
- 04 Oct 2018 According to a NeuroVive Pharmaceutical media release, biomarker analyses using samples from this study patients has been completed.
- 04 Oct 2018 Results of biomarker analyses using samples from this study patients, presented in a NeuroVive Pharmaceutical media release.
- 31 Aug 2018 Biomarkers information updated